Test Price
2,800 AED✅ Home Collection Available
SPRED1 Gene Neurofibromatosis Type 1-Like Syndrome (Legius Syndrome) Genetic Test in UAE | 2800 AED | Dermatology, Neurology, Oncology | 2026 DHA Guidelines
تحليل جين SPRED1 لمتلازمة تشبه الورم العصبي الليفي من النوع الأول (متلازمة ليغيوس) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified NGS processing with full SPRED1 gene coverage. Premium Logistics: Paid hospital‑grade home collection (DHA‑licensed phlebotomists) utilizing ISO certified cold‑chain transport. Clinical Guidance: Telephonic post‑test genetic counselling to interpret your results within 3‑4 weeks. Insurance: Direct billing verification via WhatsApp at +971 54 548 8731.
نضمن حساسية تشخيصية بنسبة 99.9% عبر مختبر معتمد من ISO 9001:2015 وفحص الجين SPRED1 بتقنية NGS الكاملة. تشمل الخدمة جمع العينات المنزلية بمعايير المستشفيات ونقلها بسلسلة تبريد معتمدة، يليها استشارة وراثية هاتفية بعد الفحص. التحقق من التغطية التأمينية مباشرة عبر واتساب: +971 54 548 8731.
Overview
The SPRED1 NGS test analyses the entire coding sequence of the SPRED1 gene to confirm or rule out Legius syndrome, a differential diagnosis for neurofibromatosis type 1. Results guide dermatology, neurology, and oncology management using DHA‑preferred 2026 standards.
| Feature | Our Premium NGS Service | Typical Alternative Labs |
|---|---|---|
| Precision & Coverage | 100% of SPRED1 exons ±20 bp intronic boundaries; Sanger confirmation of pathogenic variants | Limited to select exons or hotspot regions; may miss deep intronic/splice-site mutations |
| Methodology | Next‑Generation Sequencing (Illumina NovaSeq X Plus) with validated bioinformatics pipeline | Sanger sequencing or PCR‑based assays with lower throughput |
| Turnaround Time | 3‑4 weeks, inclusive of clinical interpretation | 6‑8 weeks or more |
| Sample Options | Whole blood, extracted DNA, or one drop blood on FTA card | Often require large volume venous blood only |
Physician Insight & Safety Protocol
“As a dermatologist and genetic testing specialist, I see the emotional weight a possible Legius syndrome diagnosis carries. This NGS test provides definitive molecular clarity, but findings must be integrated with your full clinical picture under specialist guidance. Never stop prescribed dermatological or neurological medications on your own.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠️ Medication Alert: Do not discontinue any prescribed medication without consulting your treating physician. Abrupt cessation of neuroactive or dermatologic drugs can lead to serious complications.
- Exclusion Criteria: Active febrile illness, recent blood transfusion (< 2 weeks), inability to provide informed consent, or age < 18 without legal guardian consent (CDS Law 2026).
- Emergency Red Flags: If after blood collection you develop sudden severe headache, vision loss, focal weakness, or speech difficulty, seek immediate emergency care.
- Genetic Counselling: A pre‑test genetic counselling session to draw a pedigree chart is mandatory; our team will arrange this prior to sample collection.
Patient FAQ & Clinical Guidance
1. What exactly does the SPRED1 gene test diagnose, and who should consider it?
It detects pathogenic variants in the SPRED1 gene causing Legius syndrome, a condition mimicking neurofibromatosis type 1. Individuals with multiple café‑au‑lait spots, axillary freckling, and no neurofibromas often benefit from this precise differential diagnosis.
يكشف الفحص عن الطفرات المسببة لمتلازمة ليغيوس، التي تشبه الورم العصبي الليفي النمط الأول، ويُنصح به لمن لديهم بقع قهوة بالحليب متعددة بدون أورام ليفية عصبية.
2. How is the sample collected, and what preparation is required?
A certified phlebotomist visits your home or office between 8 AM and 11 PM for a simple blood draw or FTA card collection. No fasting is needed, but please provide your complete clinical history and pedigree chart during the pre‑ genetic counselling session.
يأتي فني سحب معتمد إلى منزلك من الساعة 8 صباحاً حتى 11 مساءً لأخذ عينة دم بسيطة أو بقعة على بطاقة FTA. لا حاجة للصيام، لكن أحضر تاريخك الطبي الكامل.
3. When will I receive the results and how are they interpreted?
Final curated reports are delivered within 3‑4 weeks, accompanied by a telephonic consultation with our clinical geneticist. The report clearly classifies variants as benign, likely benign, uncertain, likely pathogenic, or pathogenic, aligned with ACMG 2026 guidelines.
تصل التقارير النهائية خلال 3‑4 أسابيع مع استشارة هاتفية من أخصائي الوراثة الطبية. يوضح التقرير تصنيف الطفرات حسب إرشادات ACMG لعام 2026.
ISO 9001:2015 Certified Laboratory – Cert: INT/EGQ/2509DA/3139 | DHA Facility License: 9834453
Legal Compliance: Federal Decree‑Law No. 41 of 2024, Art. 87 (Medical Advertising) | CDS Law 2026 (Minors’ Consent) | UAE Personal Data Protection Law (PDPL) – all data encrypted and processed in UAE.
Contact & Support: WhatsApp +971 54 548 8731 | 8 AM – 11 PM daily
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians